Recombinant human VEGF receptor-Fc fragment fusion protein(Tiantai Yinkang Biological Medicine Co Ltd)

Primary purpose: To evaluate the safety and tolerability of a single dose of IBI304 in subjects with venous occlusive macular edema, determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), and provide guidance for dose selection in Phase II clinical studies. Secondary purpose: To preliminarily evaluate the efficacy of IBI304 in subjects with venous occlusive macular edema; To determine the pharmacokinetic characteristics of IBI304 after single and multiple doses in subjects with venous occlusive macular edema.